[{"orgOrder":0,"company":"Par Health","sponsor":"Mallinckrodt Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Hormone","year":"2025","type":"Demerger","leadProduct":"Corticotropin","moa":"Melanocortin receptor 2","graph1":"Undisclosed","graph2":"Approved FDF","graph3":"Par Health","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Par Health \/ Mallinckrodt Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Par Health \/ Mallinckrodt Pharmaceuticals"}]

Find Clinical Drug Pipeline Developments & Deals by Par Health

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          CPhI India
                          Not Confirmed
                          CPhI India
                          Not Confirmed

                          Details : In a demerger deal, Corticotropin, a hormone targeting Melanocortin receptor 2, will focus on rare conditions.

                          Product Name : Acthar Gel

                          Product Type : Hormone

                          Upfront Cash : Undisclosed

                          November 10, 2025

                          Lead Product(s) : Corticotropin

                          Therapeutic Area : Neurology

                          Highest Development Status : Approved FDF

                          Sponsor : Mallinckrodt Pharmaceuticals

                          Deal Size : Undisclosed

                          Deal Type : Demerger

                          blank